|
SLC25A20 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.11555209514336E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.04585262461887E-12 |
| Normal-vs-Stage2 |
6.347800E-01 |
| Normal-vs-Stage3 |
6.43929354282591E-14 |
| Normal-vs-Stage4 |
1.62658775337832E-12 |
| Stage1-vs-Stage2 |
2.117500E-03 |
| Stage1-vs-Stage3 |
3.578100E-02 |
| Stage1-vs-Stage4 |
7.402800E-04 |
| Stage2-vs-Stage3 |
1.394910E-04 |
| Stage2-vs-Stage4 |
1.67510999999898E-05 |
| Stage3-vs-Stage4 |
1.857800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.99285032920216E-12 |
| Normal-vs-AfricanAmerican |
5.16420000096218E-08 |
| Normal-vs-Asian |
2.15150119942109E-11 |
| Caucasian-vs-AfricanAmerican |
5.595800E-01 |
| Caucasian-vs-Asian |
2.705800E-01 |
| AfricanAmerican-vs-Asian |
9.464600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.42120040367433E-10 |
| Normal-vs-Female |
5.24524867984155E-12 |
| Male-vs-Female |
4.825600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.95812288395337E-12 |
| Normal-vs-Age(41-60Yrs) |
3.6383118739991E-12 |
| Normal-vs-Age(61-80Yrs) |
2.15349999999059E-05 |
| Normal-vs-Age(81-100Yrs) |
8.000200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.477800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.525800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.077800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.879700E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.675400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.113200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.41030000000431E-06 |
| Classical-VS-Follicular |
2.07469999957688E-07 |
| Classical-VS-Other |
7.954600E-01 |
| Classical-VS-Normal |
2.16304751887719E-12 |
| Tall-VS-Follicular |
1.72883929394629E-12 |
| Tall-VS-Other |
4.083600E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
6.032200E-01 |
| Follicular-VS-Normal |
7.416200E-02 |
| Other-VS-Normal |
4.073400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.76879999980173E-07 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
9.99755833674953E-13 |
|
|
